Key Facts

Invested since 2020
Based in Bavaria

About the company

Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients. Employing the company’s proprietary ADC development approach, Tubulis will advance a variety of conjugates, unlimited by indication

Do you want to

know more about this company?

Zum Artikel

Dr. Frank Hensel Principal

Dr. Frank HenselPrincipal

Tubulis in the news

Zum Artikel

News

14. March 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Zum Artikel

News

3. May 2022

Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies

Zum Artikel

News

21. July 2020

Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates

More startups from Life Sciences